ADMA Biologics will report Q4 and 2025 financial results on February 25, 2026, followed by a conference call.
Quiver AI Summary
ADMA Biologics, Inc. has announced that it will report its fourth quarter and full year 2025 financial results on February 25, 2026, after market closure. A live conference call will be held at 4:30 p.m. ET to discuss these results and provide further company updates, with participants required to register for access details. ADMA Biologics is a biopharmaceutical company that specializes in the manufacturing and marketing of specialty biologics for immunodeficient patients and others at risk of infectious diseases. It currently offers three FDA-approved plasma-derived biologics and is developing an investigational product targeting S. pneumonia. The company operates a plasma fractionation and purification facility in Florida and owns an FDA-approved source plasma collection operation. More information is available on their website.
Potential Positives
- ADMA Biologics is set to report its fourth quarter and full year 2025 financial results, signaling transparency and accountability to investors.
- The company is hosting a live conference call to discuss its financial results, providing an opportunity for investors to engage directly with management and gain insights into future prospects.
- ADMA currently markets three FDA-approved plasma-derived biologics, showcasing its established position in the biopharmaceutical market and commitment to addressing immunodeficiencies.
- The ongoing development of SG-001, a pre-clinical hyperimmune globulin, indicates ADMA's focus on innovation and expanding its product pipeline to meet patient needs.
Potential Negatives
- The press release does not provide any specific financial performance data or highlights, which may raise concerns among investors about the company's financial health leading up to the earnings report.
- There is a lack of detail regarding ongoing product development and commercial performance, which could imply uncertainty about the company's pipeline and future growth prospects.
- The requirement for conference call participants to register for dial-in numbers and a unique PIN may lead to decreased attendance and engagement from investors and analysts.
FAQ
When will ADMA Biologics announce its 2025 financial results?
ADMA Biologics will report its fourth quarter and full year 2025 financial results on February 25, 2026.
What time is the ADMA conference call on February 25, 2026?
The conference call will begin at 4:30 p.m. ET on February 25, 2026.
How can I access the ADMA conference call?
Participants need to register for the call to receive dial-in numbers and a unique PIN.
Where can I listen to the ADMA webcast?
The live webcast can be accessed on the ADMA Biologics website during the conference call.
What products does ADMA Biologics manufacture?
ADMA manufactures three FDA-approved plasma-derived biologics for immune deficiencies and infections: ASCENIV™, BIVIGAM®, and NABI-HB®.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ADMA Insider Trading Activity
$ADMA insiders have traded $ADMA stock on the open market 10 times in the past 6 months. Of those trades, 0 have been purchases and 10 have been sales.
Here’s a breakdown of recent trading of $ADMA stock by insiders over the last 6 months:
- ADAM S GROSSMAN (President and CEO) has made 0 purchases and 10 sales selling 105,000 shares for an estimated $1,764,000.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$ADMA Revenue
$ADMA had revenues of $134.2M in Q3 2025. This is an increase of 12.0% from the same period in the prior year.
You can track ADMA financials on Quiver Quantitative's ADMA stock page.
$ADMA Hedge Fund Activity
We have seen 183 institutional investors add shares of $ADMA stock to their portfolio, and 244 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- JANUS HENDERSON GROUP PLC added 3,838,158 shares (+3906.1%) to their portfolio in Q4 2025, for an estimated $70,008,001
- CAPITAL RESEARCH GLOBAL INVESTORS added 3,383,559 shares (+104.0%) to their portfolio in Q4 2025, for an estimated $61,716,116
- OBERWEIS ASSET MANAGEMENT INC/ removed 2,712,040 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $49,467,609
- UBS GROUP AG added 2,581,670 shares (+129.9%) to their portfolio in Q4 2025, for an estimated $47,089,660
- DRIEHAUS CAPITAL MANAGEMENT LLC removed 2,477,013 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $36,313,010
- SACHEM HEAD CAPITAL MANAGEMENT LP added 2,415,000 shares (+27.0%) to their portfolio in Q4 2025, for an estimated $44,049,599
- PERPETUAL LTD removed 2,119,291 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $38,655,867
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
RAMSEY, N.J. and BOCA RATON, Fla., Feb. 18, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a U.S. based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, today announced that it will report fourth quarter and full year 2025 financial results on February 25, 2026, after the U.S. financial markets close. ADMA’s management team will host a live conference call and audio webcast on that date at 4:30 p.m. ET to discuss its financial results and other Company updates.
To access the conference call seamlessly, participants are required to register for the call here to receive the dial-in numbers and unique PIN. It is recommended that you join approximately 10 minutes prior to the event start (although you may dial in at any time during the call). Attendees who will not be asking a question during the call are encouraged to listen in to the live webcast here . An archived replay of the event will be available located under “Events & Webcasts” in the investor section of the Company’s website at https://ir.admabiologics.com/events-webcasts .
About ADMA Biologics, Inc. (ADMA)
ADMA Biologics is a U.S.-based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. ADMA currently manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV™ (immune globulin intravenous, human – slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM ® (immune globulin intravenous, human) for the treatment of PI; and NABI-HB ® (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Additionally, ADMA is developing SG-001, a pre-clinical, investigative hyperimmune globulin targeting S. pneumonia . ADMA manufactures its immune globulin products and product candidates at its FDA-licensed plasma fractionation and purification facility located in Boca Raton, Florida. Through its ADMA BioCenters subsidiary, ADMA also operates as an FDA-approved source plasma collector in the U.S., which provides its blood plasma for the manufacture of its products. ADMA’s mission is to manufacture, market and develop specialty plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases and management of immune compromised patient populations who suffer from an underlying immune deficiency, or who may be immune compromised for other medical reasons. ADMA holds numerous U.S. and foreign patents related to and encompassing various aspects of its products and product candidates. For more information, please visit www.admabiologics.com .
INVESTOR RELATIONS CONTACT:
Argot Partners | 212-600-1902 | [email protected]
